RANCHO CUCAMONGA, CA (June 4, 2020) – PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, has entered into a strategic alliance with Marathon Group, LLC and Whiting Systems, Inc. to implement PURE’s Transport Sanitation Solution across Whiting Systems, Inc.’s U.S. network of truck washing and sanitizing facilities using PURE® Hard Surface disinfectant. Marathon Group, LLC is a licensed product distributor for PURE Bioscience, Inc. and specializes in surface disinfection, sanitization, and cleaning for the transportation industry.
PURE’s Chief Executive Officer and President Tom Y. Lee said, “Whiting Systems is a leader in the transportation industry and we are pleased to welcome them as a partner in our PURE Transport Sanitation Solution program. By combining our SDC product set and this alliance, we expect that Whiting Systems’ customer base will help build the confidence of the airline industry, train industry, bus transportation industry, and commercial transit industry. We expect that our association with Whiting Systems will increase the number of blue-chip corporations and independent companies using the PURE Transport Sanitation Solution program for operator/passenger travel. Whiting Systems’ commitment to sanitizing all transportation needs, inside and out, is in line with our new PURE Certification Mitigation program designed to protect America’s transportation and logistics chain.”
“We are excited to implement the PURE Transport Sanitation Solution across Whiting Systems’ network. The environmental benefits and superior efficacy of PURE’s EPA-registered PURE Hard Surface disinfectant aligns perfectly with our sanitizing services and our commitment to provide innovative and reliable safety solutions to our customers,” said Russ Whiting, President of Whiting Systems.
About Whiting Systems, Inc.
Whiting Systems, Inc., founded in 1974, is a global leader in providing transportation disinfecting and washing systems to the leading truck, train, bus, and commercial transit companies around the world. Whiting Systems, Inc.’s accounts include all major rental companies, the airline industry, and passenger rail, bus transit, and commercial carriers. It caters to a broad spectrum of clientele and all their needs, including sanitation and occupant’s health and safety. With over 1,000 locations in the continental United States, South America, Australia, Canada, Mexico, Middle East and the United Kingdom, Whiting Systems, Inc. is the industry leader in transportation image and hygiene.
About PURE Bioscience, Inc.
PURE Bioscience, Inc. is focused on developing and commercializing our proprietary antimicrobial products primarily in the food safety arena. We provide solutions to combat the health and environmental challenges of pathogen and hygienic control. Our technology platform is based on patented, stabilized ionic silver, and our initial products contain silver dihydrogen citrate, better known as SDC. This is a broad-spectrum, non-toxic antimicrobial agent, which offers 24-hour residual protection and formulates well with other compounds. As a platform technology, SDC is distinguished from existing products in the marketplace because of its superior efficacy, reduced toxicity and mitigation of bacterial resistance. PURE is headquartered in Rancho Cucamonga, California (San Bernardino metropolitan area). Additional information on PURE is available at www.purebio.com.
Forward-looking Statements: Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Statements in this press release concerning the Company’s expectations (including with respect to the strategic alliance with Marathon Group, LLC and Whiting Systems, Inc.), plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are “forward-looking statements.” Forward-looking statements inherently involve risks and uncertainties that could cause our actual results to differ materially from any forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, the Company’s failure to implement or otherwise achieve the benefits of its proposed business initiatives and plans; economic and other disruptions resulting from COVID-19, acceptance of the Company’s current and future products and services in the marketplace, including the Company’s ability to convert successful evaluations and tests for PURE Control and PURE Hard Surface into customer orders and customers continuing to place product orders as expected and to expand their use of the Company’s products; the Company’s ability to maintain relationships with its partners and other counterparties; the Company’s ability to generate sufficient revenues and reduce its operating expenses in order to reach profitability; the Company’s ability to raise the funding required to support its continued operations and the implementation of its business plan; the ability of the Company to develop effective new products and receive required regulatory approvals for such products, including the required data and regulatory approvals required to use its SDC-based technology as a direct food contact processing aid in raw meat processing and to expand its use in OLR poultry processing; competitive factors, including customer acceptance of the Company’s SDC-based products that are typically more expensive than existing treatment chemicals; dependence upon third-party vendors, including to manufacture its products; and other risks detailed in the Company’s periodic report filings with the Securities and Exchange Commission (the SEC), including its Form 10-K for the fiscal year ended July 31, 2019 and Form 10-Q for the second fiscal quarter ended January 31, 2020. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.
Mark Elliott, VP Finance
PURE Bioscience, Inc.
Ph: (619) 596-8600 Ext: 116
Jason Rhoads, Director of Marketing and Disinfectant Sales